利培酮合用碳酸锂治疗难治性精神分裂症的对照研究

A control study on risperidone augmented with lithium carbonate in the treatment of intractable schizophrenia

目的探讨利培酮合用碳酸锂治疗难治性精神分裂症的疗效及安全性。方法将92例难治性精神分裂症患者随机分为合用药组和单用药组,合用药组以利培酮合用碳酸锂治疗,单用药组以利培酮治疗,疗程12周。采用阳性与阴性症状量表(PANSS)及治疗副反应量表(TESS)评定疗效和不良反应。结果合用药组有效率为71.7%,单用药组有效率为50%。合用药组阳性症状、精神病理在2周末已有显著下降(P<0.05),而单用药组阳性症状、精神病理在4周末才有显著下降(P<0.05或P<0.01)。两组部分在4周末均有显著下降(P<0.01),12周末两组部分比较有显著性差异(P<0.01)。两组不良反应差异无显著性(P>0.05)。结论利培酮合用碳酸锂治疗难治性精神分裂症同样安全而疗效优于单用利培酮。

Objective To explore the efficacy and safety of risperidone augmented with lithium carbonate in the treat- ment of intractable schizophrenia. Methods 92 patients with intractable schizophrenia were randomly divided into two equal groups （n =46） for a 12-week treatment. The treatment group was treated with risperidone augmented with lithium carbonate and the control group was treated with risperidone only. The efficacy and side effects were assessed with positive and negative syn- drome scale （PANSS） and treatment emergent symptom scale （TESS） respectively. Results The efficacy of the treatment group is 71.1% while the control group is 50%. Negative symptom scale score and general psychopathology score in the treat- ment group descented significantly at the 2nd weekend （P 〈0.05） while the control group till the 4th weekend （P 〈0.05 or P 〈0.01 ） . The total score of PANSS of both groups descented significantly at the 4th weekend （P 〈0. 01 ） and there is signifi- cant difference between groups （P 〈 0. 01 ） at the 12th weekend. TESS scores showes no singnificant difference between the two groups in this study （P 〈 0. 05 ） . Conclusion The treatment of risperidone augmented with lithium carbonate for intractable schizophrenia is safe and more efficient than risperidone only.